Pfizer aims ambitious PCSK9 program at payers, skeptical regulators

Tracy Staton

Tantalized by various megablockbuster projections for the  field of cholesterol drugs, has mapped out one of the most late-stage programs in the industry for RN-316. This week, the pharma giant spelled out plans for a massive cardiovascular outcomes trial to prove to and alike that the drug not only works as advertised, but delivers real value to patients.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS